Corcept Therapeutics Stock Forecast, Price & News

Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CORT shares have increased by 53.1% and is now trading at $16.76.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Corcept Therapeutics.

Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Corcept Therapeutics.

Corcept Therapeutics will be holding an earnings conference call on Tuesday, November 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Tuesday, August, 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.20 by $0.03. The biotechnology company had revenue of $88.60 million for the quarter, compared to analyst estimates of $90.13 million. Corcept Therapeutics had a net margin of 32.49% and a return on equity of 29.10%. The company's quarterly revenue was up 23.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.25 earnings per share.
View Corcept Therapeutics' earnings history.

Corcept Therapeutics updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $355-375 million, compared to the consensus revenue estimate of $368.27 million.

2 equities research analysts have issued 12-month price targets for Corcept Therapeutics' shares. Their forecasts range from $15.00 to $16.00. On average, they expect Corcept Therapeutics' share price to reach $15.50 in the next year. This suggests that the stock has a possible downside of 7.5%.
View analysts' price targets for Corcept Therapeutics.

Corcept Therapeutics saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 18,860,000 shares, a decline of 18.6% from the August 31st total of 23,160,000 shares. Based on an average daily trading volume, of 2,890,000 shares, the days-to-cover ratio is presently 6.5 days. Currently, 18.1% of the shares of the company are short sold.
View Corcept Therapeutics' Short Interest.

Some companies that are related to Corcept Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Eli Lilly and (LLY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (6.48%), LSV Asset Management (1.37%), Parallel Advisors LLC (1.12%), WINTON GROUP Ltd (0.31%), Assenagon Asset Management S.A. (0.30%) and State of New Jersey Common Pension Fund D (0.16%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck.
View institutional ownership trends for Corcept Therapeutics.

CORT stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Parallel Advisors LLC, Ingalls & Snyder LLC, LSV Asset Management, Nisa Investment Advisors LLC, Alberta Investment Management Corp, and Valeo Financial Advisors LLC. Company insiders that have sold Corcept Therapeutics company stock in the last year include Daniel N Swisher Jr, and G Leonard Baker Jr.
View insider buying and selling activity for Corcept Therapeutics.

CORT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of New Jersey Common Pension Fund D, Campbell & CO Investment Adviser LLC, Louisiana State Employees Retirement System, 6 Meridian, Robeco Institutional Asset Management B.V., Dupont Capital Management Corp, and Envestnet Asset Management Inc..
View insider buying and selling activity for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $16.76.

Corcept Therapeutics has a market capitalization of $1.94 billion and generates $306.49 million in revenue each year. The biotechnology company earns $94.18 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.

The official website for Corcept Therapeutics is www.corcept.com.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]